Read by QxMD icon Read

Borderline ovarian carcinoma

F Moro, G F Zannoni, D Arciuolo, T Pasciuto, S Amoroso, F Mascilini, S Mainenti, G Scambia, A C Testa
OBJECTIVES: To describe clinical and ultrasound findings of mucinous ovarian tumors. METHODS: Patients with a histological diagnosis of mucinous ovarian tumor who had undergone preoperative ultrasound examination were retrospectively identified from a single ultrasound center. The histological examination was performed by the same pathologist in all cases. The masses were described using the terms and definitions of the International Ovarian Tumor Analysis group...
August 12, 2016: Ultrasound in Obstetrics & Gynecology
Pinar Solmaz Hasdemir, Tevfik Guvena
Borderline ovarian tumors (BOTs) differ from the epithelial ovarian malignancies with their excellent prognosis, curability with surgery, and being seen in relatively young ages. Thus, fertility sparing and conservative surgical approaches are currently recommended. Preoperative diagnosis of BOTs can be challenging because, clinical and ultrasonographic features might overlap with invasive carcinomas and sometimes with benign adnexal masses. Certain characteristics such as stage at diagnosis, age of the patient and histologic features are important while deciding the extensiveness and the type of surgery...
July 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
Abigail Wheal, Robert Jenkins, Yoshiki Mikami, Nagindra Das, Lynn Hirschowitz
Primary mucinous carcinoma of the fallopian tube is extremely rare. We report the detailed characterization of a mucinous carcinoma arising in the fimbrial end of the fallopian tube in a 74-yr-old woman. The patient presented with recurrent urinary tract infection and urinary tract obstruction secondary to a large right ovarian mass. She had an appendicectomy as an 11 yr old. Serum CA-125 was raised at 239 U/mL. Computed tomographic scans showed bilateral, cystic ovarian tumors but no other intra-abdominal abnormality...
September 22, 2016: International Journal of Gynecological Pathology
Robert J Morgan, Deborah K Armstrong, Ronald D Alvarez, Jamie N Bakkum-Gamez, Kian Behbakht, Lee-May Chen, Larry Copeland, Marta Ann Crispens, Maria DeRosa, Oliver Dorigo, David M Gershenson, Heidi J Gray, Ardeshir Hakam, Laura J Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A Matulonis, David M O'Malley, Richard T Penson, Sanja Percac-Lima, Mario Pineda, Steven C Plaxe, Matthew A Powell, Elena Ratner, Steven W Remmenga, Peter G Rose, Paul Sabbatini, Joseph T Santoso, Theresa L Werner, Jennifer Burns, Miranda Hughes
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for the 2016 update. The new LCOHs algorithms include clear cell carcinomas, mucinous carcinomas, and grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. The LCOHs also include carcinosarcomas (malignant mixed Müllerian tumors of the ovary), borderline epithelial tumors (also known as low malignant potential tumors), malignant sex cord-stromal tumors, and malignant germ cell tumors...
September 2016: Journal of the National Comprehensive Cancer Network: JNCCN
Nara Yoon, Gun Yoon, Cheol Keun Park, Hyun-Soo Kim
Alterations in p16 protein expression have been reported to be associated with tumor development and progression. However, p16 expression status in the peritumoral stroma has been rarely investigated. We investigated the stromal p16 expression in ovarian neoplasms using immunohistochemistry, and differences in the expression status depending on the degree of malignancy and histological type were analyzed. This study included 24, 21, and 46 cases of benign, borderline, and malignant ovarian lesions, respectively, of which 29, 25, and 32 cases were serous, mucinous, and endometriosis-associated lesions...
August 27, 2016: Oncotarget
Longwen Chen, Kristina A Butler, Debra A Bell
Serous borderline tumor (SBT) involving a cervical lymph node is extremely rare. In addition, fine needle aspiration (FNA) cytology of the involved cervical lymph node shares tremendous morphologic similarity with other low-grade papillary carcinomas. Thus, it can be easily misdiagnosed as metastatic carcinoma. A 42-year-old female had a history of bilateral SBT and postbilateral salpingo-oophorectomy. She presented with left cervical lymphadenopathy 6 months later. FNA cytology showed a low-grade papillary neoplasm with psammoma bodies...
2016: CytoJournal
Nermin Koc, Selçuk Ayas, Sevcan Arzu Arinkan
Background: The objective of this study was to compare the classical method and Sectioning and Extensively Examining the Fimbriated End Protocol (SEE-FIM) in detecting microscopic lesions in fallopian tubes with gynecological lesions. Materials and Methods: From a total of 1,118 cases, 582 with various parts of both fallopian tubes sampled in three-ring-shape sections and 536 sampled with the SEE-FIM protocol were included in this study. Pathological findings of cases with endometrial carcinoma, non-uterine pelvic malignant tumor, ovarian borderline tumors, premalignancy, and benign lesions were compared...
August 19, 2016: Journal of Pathology and Translational Medicine
Stefan Cosyns, Philippe De Sutter, Herman Tournaye, Nikolaos P Polyzos
OBJECTIVE: The benefit of performing an appendectomy during the surgical treatment of a mucinous borderline ovarian tumor (mBOT) is still controversial, even though clinical guidelines recommend this procedure. PURPOSE: Our aim was to systematically assess the available evidence on appendectomy in the case of diagnosis of mBOT. METHODS: A comprehensive search of the literature was conducted using electronic databases using the search terms: (borderline OR low malignant potential) AND (appendectomy OR appendix)...
August 17, 2016: Archives of Gynecology and Obstetrics
F Moro, G F Zannoni, D Arciuolo, T Pasciuto, S Amoroso, F Mascilini, S Mainenti, G Scambia, A C Testa
OBJECTIVES: To describe clinical and ultrasound findings of mucinous ovarian tumors. METHODS: Patients with a histological diagnosis of mucinous ovarian tumor who had undergone preoperative ultrasound examination were retrospectively identified from a single ultrasound center. The histological examination was performed by the same pathologist in all cases. The masses were described using the terms and definitions of the International Ovarian Tumor Analysis group...
August 12, 2016: Ultrasound in Obstetrics & Gynecology
Giovanna Giordano, Roberto Berretta, Enrico Silini
BACKGROUND: In the ovary, sarcomatoid carcinoma has been reported only as mural nodules in epithelial malignant or borderline serous or mucinous cystic neoplasms, and in teratomas. In this paper we report a rare case of a solid sarcomatoid carcinoma of the ovary, without accompanying component of giant cells, pleomorphic cells, or glandular and other epithelial structures. CASE PRESENTATION: This case report refers to a sarcomatoid carcinoma of the ovary in in a 57 year-old woman with abdominal pain...
August 5, 2016: Diagnostic Pathology
Geunghwan Ahn, Ann K Folkins, Jesse K McKenney, Teri A Longacre
Low-grade serous carcinoma (LGSC) is an uncommon but distinct histologic subtype of ovarian carcinoma. Although the histologic features and natural history of LGSC have been described in the literature, there is no robust correlative study that has specifically addressed histologic features in correlation with clinical follow-up. To refine the criteria for invasion patterns of LGSC and determine additional clinically pertinent morphologic features of LGSC predisposing to a more aggressive clinical course, the clinicopathologic features of 52 LGSCs were evaluated and compared with those of a large series of serous borderline tumors (SBT), with and without invasive implants...
September 2016: American Journal of Surgical Pathology
Shoko Kitade, Ichiro Onoyama, Hiroaki Kobayashi, Hiroshi Yagi, Sachiko Yoshida, Masaya Kato, Ryosuke Tsunematsu, Kazuo Asanoma, Kenzo Sonoda, Norio Wake, Kenichiro Hata, Keiichi I Nakayama, Kiyoko Kato
FBXW7 is a ubiquitin ligase that mediates ubiquitylation of oncoproteins, such as c-Myc, cyclin E, Notch, and c-Jun. FBXW7 is a known tumor-suppressor gene, and mutations in FBXW7 have been reported in various human malignancies. In this study, we examined the sequences of the FBXW7 and p53 genes in 57 ovarian cancer clinical samples. Interestingly, we found no FBXW7 mutations associated with amino acid changes. We also investigated FBXW7 expression levels in 126 epithelial ovarian tumors. FBXW7 expression was negatively correlated with the malignant potential of ovarian tumors...
August 3, 2016: Cancer Science
Eveline Vancraeynest, Philippe Moerman, Karin Leunen, Frédéric Amant, Patrick Neven, Ignace Vergote
OBJECTIVES: This study aimed to determine the overall survival (OS) and progression-free interval and the influence of fertility-preserving surgery (FPS) versus radical surgery (RS) in patients with serous borderline ovarian tumor (BOT). METHODS: Clinical parameters of patients with serous BOT treated between 1993 and 2013 in one institution were retrospectively investigated. All tumors were examined by one pathologist with experience in gynecological pathology...
October 2016: International Journal of Gynecological Cancer
Min Wang, Haifen Ma
It has been suggested that Paired box gene (PAX)2 is activated by estradiol via estrogen receptor (ER)α in breast and endometrial cancer. The expression of PAX2 was restricted to ovarian serous tumors and only one case was positive in borderline mucinous tumor in our previous study. In the present study, immunohistochemistry was performed to assess the expression of ERα in 58 cases of ovarian serous tumors, including 30 serous cystadenomas, 16 borderline serous cystadenomas, 12 serous carcinomas and 67 cases of ovarian mucinous tumors, including 29 mucinous cystadenoma, 23 borderline mucinous cystadenoma and 15 mucinous carcinoma, which were the same specimens with detection of PAX2 expression...
August 2016: Molecular and Clinical Oncology
Antonio Agostini, Ioannis Panagopoulos, Ben Davidson, Claes Goran Trope, Sverre Heim, Francesca Micci
Neoplasms of the ovary are the second most common tumor of the female reproductive system, and the most lethal of the gynecological malignancies. Ovarian tumors are divided into a copious number of different groups reflecting their different features. The present study analyzed 187 ovarian tumors (39 sex-cord stromal tumors, 22 borderline tumors and 126 carcinomas) for the expression of the high-mobility group AT-hook 2 (HMGA2) gene, for mutations in the isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1), isocitrate dehydrogenase (NADP(+)) 2, mitochondrial (IDH2) and telomerase reverse transcriptase (TERT) genes, and for methylation of the O(6)-methylguanine-DNA methyltransferase (MGMT) promoter...
August 2016: Oncology Letters
Jesse K McKenney, C Blake Gilks, Steve Kalloger, Teri A Longacre
The classification of extraovarian disease into invasive and noninvasive implants predicts patient outcome in patients with high-stage ovarian serous borderline tumors (tumors of low malignant potential). However, the morphologic criteria used to classify implants vary between studies. To date, there has been no large-scale study with follow-up data comparing the prognostic significance of competing criteria. Peritoneal and/or lymph node implants from 181 patients with high-stage serous borderline tumors were evaluated independently by 3 pathologists for the following 8 morphologic features: micropapillary architecture; glandular architecture; nests of epithelial cells with surrounding retraction artifact set in densely fibrotic stroma; low-power destructive tissue invasion; single eosinophilic epithelial cells within desmoplastic stroma; mitotic activity; nuclear pleomorphism; and nucleoli...
September 2016: American Journal of Surgical Pathology
Carla Bartosch, Ana S Pires-Luís, Catarina Meireles, Manuela Baptista, Alfredo Gouveia, Carla Pinto, Kristen M Shannon, Carmen Jerónimo, Manuel R Teixeira, José M Lopes, Esther Oliva
Women with Lynch syndrome (LS) have a high risk of developing endometrial carcinoma (EC) and, less frequently, ovarian carcinoma. As EC not uncommonly is the first malignancy, prophylactic hysterectomy (PH) has been increasingly implemented. In this study, we report the clinicopathologic features of a series of 70 LS patients who underwent either PH (n=39) or nonprophylactic hysterectomy (NPH) (n=31) at 3 tertiary referral centers. Among the 39 patients with PH, 2 had endometrial tumors seen grossly, whereas 37 showed no macroscopic lesions...
September 2016: American Journal of Surgical Pathology
Rabab A A Mohammed, Rania Makboul, Dalia A H Elsers, Tarek M A M Elsaba, Abeer M A B Thalab, Omar M Shaaban
Amplification of HER-2 gene and overexpression of HER-2 receptor play a significant role in the progression of a number of malignancies such as breast cancer. Trastuzumab (anti-HER-2 therapeutic agent) has been used successfully in treatment of breast cancer. The aim of this study was to assess the pattern of HER-2 gene amplification and of HER-2 receptor expression in a spectrum of serous and mucinous ovarian tumors to determine whether HER-2 is altered in these neoplasms similar to that occurring in breast cancer...
June 15, 2016: International Journal of Gynecological Pathology
Amina A Gamal El Din, Manal A Badawi, Shereen E Abdel Aal, Nihad A Ibrahim, Fatma A Morsy, Nermeen M Shaffie
BACKDROUND: Ovarian carcinoma is a leading cause of death in gynecological malignancy. Ovarian surface epithelial serous and mucinous tumours are classified as benign, borderline, and malignant. The identification of borderline tumours most likely to act aggressively remains an important clinical issue. AIM: This work aimed to study DNA ploidy and nuclear area in ovarian serous and mucinous; benign, borderline and malignant tumours. MATERIAL AND METHODS: This study included forty ovarian (23 serous and 17 mucinous) tumours...
December 15, 2015: Open Access Macedonian Journal of Medical Sciences
Kristian Madeira, Eduardo R Dondossola, Bruna F DE Farias, Carla S Simon, Maria C M Alexandre, Bruno R Silva, Maria Inês Rosa
The objective of this work was to estimate the accuracy of mesothelin as a biomarker for ovarian cancer. A quantitative systematic review was performed. A comprehensive search of the Medline, LILACS, SCOPUS, Embase, Cochrane Central Register of Controlled Trials, Biomed Central, and ISI Web of Science databases was conducted from January 1990 to June 2015. For inclusion in this systematic review, the papers must have measured mesothelin levels in at least two histological diagnoses; ovarian cancer (borderline or ovarian tumor) vs...
May 31, 2016: Anais da Academia Brasileira de Ciências
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"